New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study-Reference-Cited by-同舟云学术

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study

Published:2022-12-09 Issue:6 Volume:12 Page:6980-6993
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Tada Toshifumi¹²^ORCID,Kumada Takashi³,Hiraoka Atsushi⁴^ORCID,Kariyama Kazuya⁵^ORCID,Tani Joji⁶,Hirooka Masashi⁷,Takaguchi Koichi⁸,Atsukawa Masanori⁹,Fukunishi Shinya¹⁰,Itobayashi Ei¹¹,Tsuji Kunihiko¹²,Tajiri Kazuto¹³,Ochi Hironori¹⁴,Ishikawa Toru¹⁵,Yasuda Satoshi¹⁶,Ogawa Chikara¹⁷,Toyoda Hidenori¹⁶^ORCID,Hatanaka Takeshi¹⁸^ORCID,Nishimura Takashi¹^ORCID,Kakizaki Satoru¹⁹,Kawata Kazuhito²⁰,Shimada Noritomo²¹,Tada Fujimasa⁴,Nouso Kazuhiro⁵,Tsutsui Akemi⁸,Ohama Hideko⁴,Morishita Asahiro⁶,Nagano Takuya⁸,Itokawa Norio⁹,Okubo Tomomi⁹,Arai Taeang⁹,Kosaka Hisashi²²,Imai Michitaka¹⁵,Naganuma Atsushi²³^ORCID,Nakamura Shinichiro²,Koizumi Yohei⁷,Kaibori Masaki²²,Iijima Hiroko¹,Hiasa Yoichi⁷^ORCID,

Affiliation:

1. Department of Internal medicine, Division of Gastroenterology and Hepatology Hyogo Medical University Hyogo Japan

2. Department of Internal Medicine Japanese Red Cross Himeji Hospital Hygo Japan

3. Department of Nursing Gifu Kyoritsu University Gifu Japan

4. Gastroenterology Center Ehime Prefectural Central Hospital Ehime Japan

5. Department of Gastroenterology Okayama City Hospital Okayama Japan

6. Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan

7. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan

8. Department of Hepatology Kagawa Prefectural Central Hospital Kagawa Japan

9. Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan

10. Department of Gastroenterology Osaka Medical and Pharmaceutical University Osaka Japan

11. Department of Gastroenterology Asahi General Hospital Chiba Japan

12. Center of Gastroenterology Teine Keijinkai Hospital Hokkaido Japan

13. Department of Gastroenterology Toyama University Hospital Toyama Japan

14. Hepato‐biliary Center Japanese Red Cross Matsuyama Hospital Ehime Japan

15. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

16. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu Japan

17. Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Kagawa Japan

18. Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Gunma Japan

19. Department of Clinical Research National Hospital Organization Takasaki General Medical Center Gunma Japan

20. Department of Hepatology Hamamatsu University School of Medicine Shizuoka Japan

21. Division of Gastroenterology and Hepatology Otakanomori Hospital Chiba Japan

22. Department of Surgery Kansai Medical University Osaka Japan

23. Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Gunma Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5495

Reference36 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

4. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison

5. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated fibrinogen-albumin ratio is an adverse prognostic factor for patients with primarily resected gastroesophageal adenocarcinoma;2024-08-18

2. Decoding the Prognostic Significance and Therapeutic Implications of Inflammation-Based Scores in Hepatocellular Carcinoma: A Comprehensive Review;Cancers;2024-07-15

3. Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab;Hepatology Research;2024-06-15

4. A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy;Cancer Immunology, Immunotherapy;2024-06-04

5. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial;Alimentary Pharmacology & Therapeutics;2024-05-08